InvestorsHub Logo
Followers 15
Posts 646
Boards Moderated 0
Alias Born 04/21/2014

Re: Jonnyo07 post# 103890

Wednesday, 03/02/2016 2:09:52 PM

Wednesday, March 02, 2016 2:09:52 PM

Post# of 278158
I don't know for MS, but I always expected that crossbreeding would eventually be required for DS simply because of what was stated in an old PR dated May 31, 2011:

Kraig Biocraft Laboratories, Inc. (PINKSHEETS: KBLB) announced that it successfully mated its transgenic silkworms, which produce recombinant spider silk, with a physically larger commercial strain of the domesticated silkworm. The resulting hybrid silkworms are larger than Kraig’s original transgenic silkworms and are also producing significantly larger recombinant silk cocoons.

Independent laboratory testing confirmed that the transgenic/commercial silkworm hybrids are producing silk which is significantly stronger and more flexible than that of the original commercial strain. The new recombinant spider silk is a composite silk composed of both native silkworm silk proteins and spider silk proteins (as in the original Kraig transgenic silkworm whose development was announced in late September).

Kim Thompson, the Company’s CEO and Founder, stated, “The new hybrid was specifically designed for commercialization and has been designated ‘Monster Hybrid,’ which is the successful cross between our transgenic silkworms and a much larger commercial strain.

“The result is a large, robust, commercial sized silkworm which spins a larger commercial sized cocoon composed of recombinant spider silk like the original transgenic. The new hybrid was specifically designed to generate greater recombinant silk production capacity than our original first generation transgenic.”

“This larger hybrid transgenic will be the platform for our commercialization ramp up,” Thompson continued. “Now that the strength and elasticity qualities have been confirmed, we can move forward with cultivating the hybrids in commercially viable quantities. We are working diligently to increase our stock of the new strain in order to increase our production capacity.”



My guess is that they are going to be focusing on commercializing DS at their pilot production facility and not worry about MS at this time.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent KBLB News